What are the Historical Developments and Current Growth Metrics of the Pharmaceutical Continuous Manufacturing Market?
The pharmaceutical continuous manufacturing market has seen considerable growth due to a variety of factors.
•The market size of pharmaceutical continuous manufacturing has seen swift growth in recent years. It is predicted to expand from a value of $2.47 billion in 2024 to $2.72 billion in 2025, experiencing a compound annual growth rate (CAGR) of 10.2%.
The escalating growth in the historical period can be ascribed to improved quality and efficiency, decreased time-to-market, cost and operational efficiency reduction, as well as regulatory assistance and guidance, flexibility and scalability.
What Does Future Hold for The Pharmaceutical Continuous Manufacturing Market Size?
The pharmaceutical continuous manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• We can anticipate a swift expansion in the pharmaceutical continuous manufacturing market in the coming years, with an estimated valuation of $4.15 billion by 2029, representing a compound annual growth rate (CAGR) of 11.2%.
Factors contributing to this predicted growth during the forecast period include an uptick in the production of generic drugs, biopharmaceutical manufacturing, personalized medicine manufacturing, and a shift towards patient-oriented practices. Key trends projected for the forecast period encompass the implementation of continuous manufacturing, the incorporation of process analytical technology, the application of advanced automation and robotics, strategic alliances and partnerships, as well as digitalization and connectivity.
What Key Factors and Trends are Driving the Growth of the Pharmaceutical Continuous Manufacturing Market?
The escalating incidence of numerous long-term diseases is anticipated to fuel the expansion of the pharmaceutical continuous manufacturing market in the future. These ongoing disorders, which last a year or more, necessitate persistent medical care and disrupt day-to-day routines. Continuous manufacturing practices in the pharma industry enhance drug production, leading to improved efficiency and reduced expenses. Moreover, it facilitates wider availability of essential medicines, crucial for controlling long-term health conditions requiring consistent medication. For example, data from a report released by the National Association of Chronic Disease Directors (NACDD), a not-for-profit US Public Health organization focusing on chronic disease programs, in April 2022 revealed that nearly 60% of American adults are living with at least one chronic disease. Additionally, about 40% of adult Americans are contending with multiple chronic conditions (MCC). This is projected to have a $2 trillion annual impact on the US economy or $8,600 per individual by 2030. Consequently, the rising incidence of numerous chronic diseases is set to bolster the pharmaceutical continuous manufacturing market.
What are the Market Segments in the Pharmaceutical Continuous Manufacturing Market?
The pharmaceutical continuous manufacturing market covered in this report is segmented –
1) By Product: Integrated Continuous System, Control And Software, Semi-Continuous System
2) By Therapeutics Type: Large Molecule, Small Molecule
3) By Formulation: Solid Formation, Liquid And Semi-Solid Formation
4) By Application: Final Drug Product Manufacturing, Active Pharmaceutical Ingredient (API) Manufacturing
5) By End-Users: Pharmaceutical Companies, Contract Manufacturing Organization, Other End-Users
Subsegments:
1) By Integrated Continuous System: Continuous Mixer Systems, Continuous Granulation Systems, Continuous Tablet Press Systems, Continuous Coating Systems
2) By Control and Software: Process Analytical Technology (PAT) Tools, Manufacturing Execution Systems (MES), Control Software for Automation, Data Management and Visualization Software
3) By Semi-Continuous System: Batch-to-Continuous Transition Systems, Hybrid Systems, Semi-Continuous Granulation and Drying Systems
Pre-Book The Pharmaceutical Continuous Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Pharmaceutical Continuous Manufacturing Market?
The increasing presence of technological advancements is a noteworthy trend in the pharmaceutical continuous manufacturing market. Leading companies in this market are introducing novel products to uphold their market position. For instance, The United States Pharmacopeia (USP), a US-based nonprofit holding both the trademark and copyright on the Pharmacopeia National Formulary (USP-NF), unveiled the USP Advanced Manufacturing Technology Lab in December 2022. The lab launched R&D analytical solutions to facilitate drug manufacturers in integrating advanced manufacturing technologies, including pharmaceutical continuous manufacturing (PCM). This move aims to enhance geographic diversity in pharmaceutical production and bolster the medicine supply chain's resilience. It further seeks to detail materials and establish methods that ensure the quality of PCM-based drugs.
Who Are the Key Players in the Pharmaceutical Continuous Manufacturing Market?
Major companies operating in the pharmaceutical continuous manufacturing market include:
• Pfizer Inc.
• Robert Bosch GmbH
• Siemens AG
• Novartis AG
• Thermo Fisher Scientific Inc.
• GlaxoSmithKline Plc.
• Eli Lilly and Company
• Corning Inc.
• Vertex Pharmaceuticals
• Lonza Group Ltd.
• GEA Group AG
• Catalent Inc.
• Mettler Toledo
• Patheon
• Cytiva
• Samsung Biologics Co.Ltd.
• WuXi Biologics
• Syntegon Technology GmbH
• Coperion GmbH
• Hosokawa Micron Group
• FUJIFILM Diosynth Biotechnologies
• Leistritz AG
• Glatt GmbH
• Freund-Vector Corp.
• SK biotek Co. Ltd.
• Gericke AG
• GEBRÜDER LÖDIGE MASCHINENBAU GmbH
• Munson Machinery Company Inc.
• L.B. Bohle Maschinen und Verfahren GmbH
• KORSCH AG
• Chemtrix BV
What are the Regional Insights into the Pharmaceutical Continuous Manufacturing Market?
Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
